In contrast to our results, reduced expression of RhoGDI2 has been demonstrated in bladder cancer (Theodorescu et al, 2004) and cervical SCC (Bae et al, 2005) and was associated with decreased survival in bladder cancer (Theodorescu et al, 2004) and lymph node metastasis in breast cancer (Hu et al, 2007). Here, ARHGDIB is linked to breast cancer.